- Invitae is among the companies pioneering genomics. The company is building a platform that can use DNA to drive smarter healthcare decision-making throughout various life stages.
- However, the company continues to aggressively burn cash. The company has had many equity raises that have continually diluted long-term shareholders.
- The potential of genomics is huge, and the story remains in early innings. However, investors should be aware that Invitae's continued dilution stunts investment upside.
For further details see:
Invitae: Dilution Is Stunting Shareholders